Shanghai-based Ji Xing Pharmaceuticals, supported by RTW Investments, has secured a licensing agreement with Biogen (NASDAQ: BIIB) for the global clinical development rights to the US company’s pipeline candidate BIIB131. The terms of the deal include an undisclosed upfront payment, milestone payments, and royalties on future global sales.
BIIB131 is being developed as a therapy for acute ischemic stroke (AIS), designed to extend the treatment window by restoring critical blood flow post-stroke, thereby enabling more patients to access current standard treatments. A Phase II study conducted in Japan demonstrated that patients receiving BIIB131 exhibited significant improvements in clinical efficacy after 90 days compared to those on placebo, particularly among patients with minimal or no neurological deficits.- Flcube.com
